
GLP-1 Agonists Reduce Recurrent Atrial Fibrillation
SAN DIEGO — Patients with obesity and diabetes are at a substantially reduced risk of having a recurrence of atrial fibrillation (AF) after ablation if they are taking a glucagon-like peptide 1 (GLP-1) receptor agonist vs another diabetes drug, according …